546 related articles for article (PubMed ID: 20855664)
1. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
[TBL] [Abstract][Full Text] [Related]
2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS; Latini R; Florea VG; Kuskowski MA; Rector T; Masson S; Signorini S; Mocarelli P; Hester A; Glazer R; Cohn JN;
Circulation; 2005 Sep; 112(10):1428-34. PubMed ID: 16129801
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
Kempf T; von Haehling S; Peter T; Allhoff T; Cicoira M; Doehner W; Ponikowski P; Filippatos GS; Rozentryt P; Drexler H; Anker SD; Wollert KC
J Am Coll Cardiol; 2007 Sep; 50(11):1054-60. PubMed ID: 17825714
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
[TBL] [Abstract][Full Text] [Related]
6. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
[TBL] [Abstract][Full Text] [Related]
7. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Anand IS; Kuskowski MA; Rector TS; Florea VG; Glazer RD; Hester A; Chiang YT; Aknay N; Maggioni AP; Opasich C; Latini R; Cohn JN
Circulation; 2005 Aug; 112(8):1121-7. PubMed ID: 16103233
[TBL] [Abstract][Full Text] [Related]
8. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN
Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
Wollert KC; Kempf T; Peter T; Olofsson S; James S; Johnston N; Lindahl B; Horn-Wichmann R; Brabant G; Simoons ML; Armstrong PW; Califf RM; Drexler H; Wallentin L
Circulation; 2007 Feb; 115(8):962-71. PubMed ID: 17283261
[TBL] [Abstract][Full Text] [Related]
11. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Baruch L; Glazer RD; Aknay N; Vanhaecke J; Heywood JT; Anand I; Krum H; Hester A; Cohn JN
Am Heart J; 2004 Dec; 148(6):951-7. PubMed ID: 15632877
[TBL] [Abstract][Full Text] [Related]
12. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
Butler J; Anand IS; Kuskowski MA; Rector T; Carson P; Cohn JN;
Congest Heart Fail; 2010; 16(5):191-5. PubMed ID: 20887614
[TBL] [Abstract][Full Text] [Related]
13. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction.
Kempf T; Björklund E; Olofsson S; Lindahl B; Allhoff T; Peter T; Tongers J; Wollert KC; Wallentin L
Eur Heart J; 2007 Dec; 28(23):2858-65. PubMed ID: 17977844
[TBL] [Abstract][Full Text] [Related]
14. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.
Lankeit M; Kempf T; Dellas C; Cuny M; Tapken H; Peter T; Olschewski M; Konstantinides S; Wollert KC
Am J Respir Crit Care Med; 2008 May; 177(9):1018-25. PubMed ID: 18263797
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
16. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Krum H; Latini R; Maggioni AP; Anand I; Masson S; Carretta E; Ingrillì F; Pettinati G; Glazer R; Tognoni G; Cohn J
Int J Cardiol; 2007 Jun; 119(1):48-53. PubMed ID: 17049646
[TBL] [Abstract][Full Text] [Related]
17. Growth-differentiation factor-15 in heart failure.
Kempf T; Wollert KC
Heart Fail Clin; 2009 Oct; 5(4):537-47. PubMed ID: 19631178
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
Anand IS; Rector TS; Kuskowski M; Snider J; Cohn JN
Circ Heart Fail; 2014 May; 7(3):418-26. PubMed ID: 24622243
[TBL] [Abstract][Full Text] [Related]
20. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
